Purina Petcare sued over antimicrobial biotechnology
Kane Biotech alleges that a Nestlé patent application makes improper use of Kane Biotech’s patent rights.
Kane Biotech Inc. filed a lawsuit against Nestec, Ltd. and Nestlé Purina Petcare Global Resources, Inc. for breach of agreements between the parties, and misappropriation of Kane Biotech’s biotechnology trade secrets and intellectual property.
In the six-count complaint filed under seal in United States federal court in Missouri, Kane Biotech alleges, amongst other improper activities, that a Nestlé patent application makes improper use of Kane Biotech’s patent rights for oral care, personal care and wound care antimicrobial and anti-biofilm technologies that the Kane Biotech developed.
"Kane Biotech has invested significantly in its intellectual property and it will vigorously protect and defend its interests and the interests of its shareholders against anyone who seeks to profit from it without proper compensation to our Corporation,” Mark Ahrens-Townsend, president and CEO of Kane Biotech, said in a press release.
About Kane Biotech Inc.
Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms
Kane Biotech has a portfolio of biotechnologies, intellectual property (75 patents and patents pending, trade secrets and trademarks) and products developed by the corporation’s own biofilm research expertise and acquired from research institutions. StrixN, DispersinB, Aledex, bluestem, AloSera, coactiv and Kane are trademarks of Kane Biotech Inc.
About Nestle Purina Petcare
Nestlé Purina claims three headquarters globally: St. Louis, Missouri, USA, for its North American and Latin American operations; Lausanne, Switzerland, in Europe; and Sydney, Australia, covering Asia, Oceania and Africa. Its parent company Nestlé's world headquarters are in Vevey, Switzerland. Purina topped US$12 billion in sales in 2016, a five percent increase for the year.